Correction to: npj Breast Cancer https://doi.org/10.1038/s41523-023-00553-y, published online 21 June 2023
“In this article the affiliation details for Author’s Jinfeng Li, Yuntao Xie, and Tianfeng Wang were incorrectly given as ‘Cancer Hospital, Chinese Academy of Medical Sciences, Breast Cancer Department, Beijing, China’ but should have been ‘Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China’. The original article has been corrected.“
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yang, Y., He, Y., Fan, Z. et al. Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial. npj Breast Cancer 9, 62 (2023). https://doi.org/10.1038/s41523-023-00567-6
Published:
DOI: https://doi.org/10.1038/s41523-023-00567-6
